清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Assessing Endoscopic Ultrasound-Guided Radiofrequency Ablation in Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Center Historic Cohort Study.

医学 射频消融术 内镜超声 胰腺导管腺癌 腺癌 放射科 临床终点 队列 胰腺癌 癌症 烧蚀 外科 内科学 随机对照试验
作者
Carlos Robles‐Medranda,Raquel Del Valle,Miguel Puga‐Tejada,Martha Arevalo-Mora,Domenica Cunto,María Egas-Izquierdo,Lorena Estrada-Guevara,Orlando Bunces-Orellana,Daniel Moreno-Zambrano,Juan Alcívar-Vásquez,Haydee Alvarado‐Escobar,Ruxandra C. Merfea,Jonathan Barreto-Perez,Jorge Rodríguez,Daniel Calle-Loffredo,Hannah Pitanga‐Lukashok,Jorge Baquerizo‐Burgos,Daniela Tabacelia
出处
期刊:Gastrointestinal Endoscopy [Elsevier BV]
卷期号:100 (2): 250-258 被引量:3
标识
DOI:10.1016/j.gie.2024.03.023
摘要

Background /aims: Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) has emerged as an alternative for the local treatment of unresectable pancreatic ductal adenocarcinoma (PDAC). We aim to assess the feasibility and safety of EUS-RFA in patients with unresectable PDAC. Methods The following was a historic cohort compounded by locally advanced (LA) and metastatic (m) PDAC naïve patients, who underwent EUS-RFA between October 2019 to March 2022. EUS-RFA was performed with a 19-g needle electrode with a 10 mm active tip for energy delivery. Study primary endpoints were feasibility, safety, and clinical follow-up; secondary endpoints were performance status (PS), local control (LC) and overall survival (OS). Results Twenty-six patients were selected: 15/26 LA-PDAC and 11/26 mPDAC. Technical success was achieved in all patients with no major adverse events. Six months after EUS-RFA, OS was 11/26 (42.3%), with significant PS improvement (P=.03). LC was achieved, with tumor reduction from 39.5 to 26 mm (P=.04). Post-treatment hypodense necrotic area was observed at six-month follow-up in 11/11 alive cases. Metastatic disease was a significant factor for OS worsening (HR 5.021; IC 95% 1.589 - 15.87; P=.004) Conclusions EUS-RFA of pancreatic adenocarcinoma is a minimally invasive and safe technique that may have an important role as targeted therapy for local treatment of unresectable cases, as well as an alternative for poor surgical candidates. Also, RFA may play a role in downstaging cancer with potential OS increase in non-metastatic cases. Large prospective cohorts are required to evaluate this technique in clinical practice. /aims: Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) has emerged as an alternative for the local treatment of unresectable pancreatic ductal adenocarcinoma (PDAC). We aim to assess the feasibility and safety of EUS-RFA in patients with unresectable PDAC. The following was a historic cohort compounded by locally advanced (LA) and metastatic (m) PDAC naïve patients, who underwent EUS-RFA between October 2019 to March 2022. EUS-RFA was performed with a 19-g needle electrode with a 10 mm active tip for energy delivery. Study primary endpoints were feasibility, safety, and clinical follow-up; secondary endpoints were performance status (PS), local control (LC) and overall survival (OS). Twenty-six patients were selected: 15/26 LA-PDAC and 11/26 mPDAC. Technical success was achieved in all patients with no major adverse events. Six months after EUS-RFA, OS was 11/26 (42.3%), with significant PS improvement (P=.03). LC was achieved, with tumor reduction from 39.5 to 26 mm (P=.04). Post-treatment hypodense necrotic area was observed at six-month follow-up in 11/11 alive cases. Metastatic disease was a significant factor for OS worsening (HR 5.021; IC 95% 1.589 - 15.87; P=.004) EUS-RFA of pancreatic adenocarcinoma is a minimally invasive and safe technique that may have an important role as targeted therapy for local treatment of unresectable cases, as well as an alternative for poor surgical candidates. Also, RFA may play a role in downstaging cancer with potential OS increase in non-metastatic cases. Large prospective cohorts are required to evaluate this technique in clinical practice.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
苗苗完成签到,获得积分10
刚刚
linj完成签到,获得积分10
9秒前
风信子完成签到,获得积分10
16秒前
17991完成签到,获得积分10
23秒前
瘦瘦的如冰完成签到,获得积分10
23秒前
berry完成签到,获得积分10
26秒前
Jasonkun完成签到,获得积分10
27秒前
冷傲的月饼完成签到,获得积分10
32秒前
jlin完成签到,获得积分10
34秒前
qin完成签到 ,获得积分10
34秒前
muriel完成签到,获得积分0
40秒前
冷静的尔竹完成签到,获得积分10
41秒前
creep2020完成签到,获得积分0
42秒前
悦耳乘风完成签到,获得积分10
53秒前
珈沐完成签到,获得积分10
55秒前
e746700020完成签到,获得积分10
59秒前
59秒前
开关盒完成签到,获得积分10
1分钟前
务实的海豚完成签到,获得积分10
1分钟前
温柔的海秋完成签到,获得积分10
1分钟前
冰河完成签到 ,获得积分10
1分钟前
追寻书本完成签到,获得积分10
1分钟前
yang完成签到 ,获得积分10
1分钟前
tszjw168发布了新的文献求助10
1分钟前
忘忧Aquarius完成签到,获得积分0
1分钟前
含蓄的芝麻完成签到,获得积分10
1分钟前
spinon完成签到,获得积分10
2分钟前
冷傲的夜白完成签到,获得积分10
2分钟前
典雅的念梦完成签到,获得积分10
2分钟前
芒果Mango完成签到,获得积分10
2分钟前
怕黑的妖丽完成签到,获得积分10
2分钟前
淡然的代灵完成签到,获得积分10
3分钟前
3分钟前
水煮电吹风的应助被CHANGE采纳,获得10
3分钟前
还单身的忆雪完成签到,获得积分10
3分钟前
迷路的穆完成签到,获得积分10
3分钟前
糟糕的问丝完成签到,获得积分10
3分钟前
3分钟前
CHENG发布了新的文献求助30
3分钟前
自信夜春发布了新的文献求助10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185453
求助须知:如何正确求助?哪些是违规求助? 9574168
关于积分的说明 21834462
捐赠科研通 7783010
什么是DOI,文献DOI怎么找? 3434570
关于科研通互助平台的介绍 2558900
邀请新用户注册赠送积分活动 2481326